NGM Aperçu des actions
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 0/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
NGM Biopharmaceuticals, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$1.54 |
| Plus haut sur 52 semaines | US$4.69 |
| Plus bas sur 52 semaines | US$0.60 |
| Bêta | 1.27 |
| 1Variation sur 1 mois | 1.32% |
| Variation sur 3 mois | 14.93% |
| Variation sur 1 an | -59.79% |
| 3Variation sur 3 ans | -93.94% |
| Variation sur 5 ans | -90.41% |
| Évolution depuis l'introduction en bourse | -89.52% |
Nouvelles et mises à jour récentes
Recent updates
What NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) 32% Share Price Gain Is Not Telling You
Dec 19
We're A Little Worried About NGM Biopharmaceuticals' (NASDAQ:NGM) Cash Burn Rate
Oct 05Some Analysts Just Cut Their NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Estimates
Aug 09Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Could Be Quite Risky
Jun 27NGM Biopharmaceuticals, Inc.'s (NASDAQ:NGM) Business Is Trailing The Industry But Its Shares Aren't
Apr 17We Think NGM Biopharmaceuticals (NASDAQ:NGM) Needs To Drive Business Growth Carefully
Dec 20NGM Biopharma sinks ~72% after phase 2 trial of its eye degeneration treatment fails
Oct 17NGM Biopharmaceuticals appoints CFO Siobhan Nolan Mangini to the additional role of President
Jun 30NGM Biopharmaceuticals: Eye Disorder Data Due Second Half Of 2022
Jun 21Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jun 15Analysts Are Betting On NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) With A Big Upgrade This Week
May 09NGM Biopharmaceuticals: How They Changed A Dead End To A Crossroad
Apr 26Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Feb 21We're Hopeful That NGM Biopharmaceuticals (NASDAQ:NGM) Will Use Its Cash Wisely
Nov 08Companies Like NGM Biopharmaceuticals (NASDAQ:NGM) Are In A Position To Invest In Growth
Jul 09NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Mar 06Rendement pour les actionnaires
| NGM | US Pharmaceuticals | US Marché | |
|---|---|---|---|
| 7D | -3.1% | -1.4% | 0.3% |
| 1Y | -59.8% | 10.8% | 31.1% |
Rendement vs Industrie: NGM a sous-performé le secteur US Pharmaceuticals qui a rapporté 10.8 % au cours de l'année écoulée.
Rendement vs marché: NGM a sous-performé le marché US qui a rapporté 31.1 % au cours de l'année écoulée.
Volatilité des prix
| NGM volatility | |
|---|---|
| NGM Average Weekly Movement | 10.3% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: Le cours de l'action de NGM a été volatil au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de NGM ( 10% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2007 | 138 | David Woodhouse | www.ngmbio.com |
NGM Biopharmaceuticals, Inc. Résumé des fondamentaux
| NGM statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$128.53m |
| Bénéfices(TTM) | -US$142.37m |
| Recettes(TTM) | US$4.42m |
29.1x
Ratio P/S-0.9x
Ratio P/ELe site NGM est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| NGM compte de résultat (TTM) | |
|---|---|
| Recettes | US$4.42m |
| Coût des recettes | US$114.23m |
| Marge brute | -US$109.81m |
| Autres dépenses | US$32.56m |
| Les revenus | -US$142.37m |
Derniers bénéfices déclarés
Dec 31, 2023
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -1.71 |
| Marge brute | -2,486.12% |
| Marge bénéficiaire nette | -3,223.34% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de NGM?
Voir les performances historiques et les comparaisons